TLDR:
- J.P. Morgan’s private financing arm has closed an inaugural life sciences fund of more than $500 million to support private biotechs and build value for existing portfolio companies.
- The fund, named “270 Life Sciences Private Capital Fund I,” will invest in biotechs across different stages, modalities, and therapeutic indications, with early investments in areas such as cardiometabolic disease, oncology, immunology, and genetic medicines.
J.P. Morgan’s Life Sciences Private Capital aims to mentor a new generation of biotech founders and executives as part of their growth investing strategy.
J.P. Morgan venture capital (VC) biotech venture capital Emerging Biopharma biotech investing Biotech Venture Capital Connect The Team Advertise Join Us Newsletters Resources RSS Feeds Our Brands Fierce Pharma Fierce Biotech Fierce Healthcare Our Events Life Sciences Events ©2024 Questex LLC All rights reserved. Terms of use Privacy Policy Privacy Settings
